Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 19/20 | 0.78 |
| ▸ | ITGA4 | P13612 | 19/20 | 0.78 |
| ▸ | ITGB7 | P26010 | 15/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5160689 | 0.88 | ITGB1 (1.00) | ITGB1ITGA4ITGB7 | |
| SCHEMBL15149714 | 0.87 | ITGB1 (0.77) | ITGB1ITGA4ITGB7 | |
| SCHEMBL15152258 | 0.87 | ITGB1 (0.77) | ITGB1ITGA4ITGB7 | |
| SCHEMBL15149391 | 0.85 | ITGB1 (0.71) | ITGB1ITGA4ITGB7 | |
| SCHEMBL15152299 | 0.85 | ITGB1 (0.71) | ITGB1ITGA4ITGB7 | |
| SCHEMBL16419910 | 0.84 | ITGB1 (0.81) | ITGB1ITGA4ITGB7 | |
| SCHEMBL20387808 | 0.83 | ITGB1 (0.70) | ITGB1ITGA4ITGB7 | |
| SCHEMBL15142822 | 0.82 | ITGB1 (0.54) | ITGB1ITGA4ITGB7 | |
| SCHEMBL5162175 | 0.81 | ITGB1 (0.88) | ITGB1ITGA4ITGB7 | |
| SCHEMBL5164143 | 0.78 | ITGA4 (0.64) | ITGB1ITGA4ITGB7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9447035-B2 | Integrin antagonist conjugates for targeted delivery to cells expressing VLA-4 | HOFFMANN-LA ROCHE INC. (US) | 2016-09-20 | — | — | US | disclosed |
| US-20150031715-A1 | INTEGRIN ANTAGONIST CONJUGATES FOR TARGETED DELIVERY TO CELLS EXPRESSING VLA-4 | HOFFMANN-LA ROCHE INC. | 2015-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031715-A1 | INTEGRIN ANTAGONIST CONJUGATES FOR TARGETED DELIVERY TO CELLS EXPRESSING VLA-4 | ITGAV, ITGA1, ITGA4 | ITGB1 6/4885ITGA4 3/4885ITGB7 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.